NADP Annual Meeting, 22 May 2019, Paushuize, Utrecht ‘Accelerating antibiotic development in Europe’

16 April 2019

NADP logo

The Netherlands Antibiotic Development Platform (NADP) is organizing its second annual meeting, titled ‘Accelerating antibiotic development in Europe‘.

The symposium will take place on 22 May 2019, 12:00 – 17:00 hrs. The venue of the meeting is Paushuize, Kromme Nieuwegracht 49, 3512 HE Utrecht. Participation is free, but registration is required through https://goo.gl/forms/gfLeU092Cx1BuHho2.

Prior to the symposium (between 9:30 – 12:00 hrs), we offer you the possibility to meet with Seamus O’Brian from the Global Antibiotic Research and Development Partnership (GARDP). GARDP (www.gardp.org) is a not-for-profit R&D organization that addresses global public health needs by developing and delivering new or improved antibiotic treatments, while endeavoring to ensure their sustainable access. If you are interested in scheduling an appointment (20-30 min.), please let us know by mailing your request to [email protected].

Programme

12:00-13:00
Registration | light lunch provided
13:00-13:10 Welcome
13:10-13:20 NADP update
Cees de Joncheere, chairman NADP Executive Board
13:20-14:05 Bacteriophages and infection, an alternative treatment or an evidence-based alternative?
Colin Hill, University College Cork, Ireland
14:05-14:25 GARDP: Public health driven antibiotic development
Seamus O’Brian, GARDP
14:25-14:45 NADP Vouchers: Next generation antibiotics to fight global antimicrobial resistance
Leonie de Best, Madam Therapeutics
14:45-15:15 Break
15:15-16:00 Unconventional strategies to find drugs aganst an unconvential pathogen: how to tackle TB
Wilbert Bitter, VU University & Amsterdam UMC
16:00-16:20 Towards a European clinical trial network for new antimicrobial agents
Marc Bonten, UMC Utrecht
16:20-16:40 NACTAR: The lugdunomycins, a new class of polyketide antibiotics with unique chemical scaffold
Gilles van Wezel, Leiden University
16:40-17:00 NACTAR: Boosting host immunity against bacterial infections via therapeutic antibodies
Frank Beurskens, Genmab
17:00-18:00 Drinks